SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Composite collage picture image of man slide down arrow recession statistics data weird freak bizarre unusual fantasy billboard comics.
MASH
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout.
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.
Collaboration
Alphabet Subsidiary Calico Colors In Up To $570M+ Aging Deal With China’s Mabwell
Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Profile view, and Mental Illness
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to signals of drug activity, William Blair said, though the analysts pointed to other indications as potentially more promising for future development.
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Medical characters fighting the epidemic flat vector concept operation hand drawn illustration
Obesity
Analysts Home In on Safety as Novo, Lilly, Amgen Highlight Weight Loss Data at ADA
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts parsing the data presented at the American Diabetes Association annual meeting this week.
June 27, 2025
 · 
5 min read
 · 
Heather McKenzie
Government
Trump’s CDC Pick Says Vaccines Are Safe, Promises To Keep Them Available
Susan Monarez, already acting director of the CDC, said during her confirmation hearing that she sees no causal link between vaccines and autism.
June 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Successful businessman standing in front of multiple pathways, making a decision for the right move. A symbol of great investment and positive progress in the development of business. stock illustration
Mergers & acquisitions
Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks
Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing than normal” given the regulatory turmoil it revealed.
June 26, 2025
 · 
4 min read
 · 
Annalee Armstrong
Strong Business Partnership and teamwork metaphor as two different groups joining together with a handshake represented by trees and stronk roots.
Deals
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal
Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic mitochondria.
June 26, 2025
 · 
1 min read
 · 
Annalee Armstrong
World heart day. Sketch style human heart. Retro halftone hands reaching out to each other. Modern collage. Valentines day banner. Healthcare medical concept. Healthy lifestyle.
Cardiovascular disease
Novartis Makes Potential $750M+ Bet Per Cardiovascular Disease Target in Another Flagship Pact
Flagship Pioneering’s ProFound Therapeutics will use its proprietary technology to mine the expanded proteome for novel cardiovascular therapeutics. Novartis has promised to pay up to $750 million per target, though it has not specified how many targets it will go after.
June 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Health and Human Services Secretary Robert F. Kennedy Jr. makes remarks at an event announcing the MAHA (Make America Healthy Again) Commission, Thursday, May 22, 2025, in the East Room of the White House. (Official White House Photo by Joyce N. Boghosian)
Vaccines
RFK Cuts U.S. Funding From Vaccine Alliance Gavi, Claims Group ‘Ignored the Science’
Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety seriously” by considering “the best science available.”
June 26, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS